Skip to content

Impact of Remote Ischemic Postconditioning on Autonomic Function in Stroke Patients

Impact of Remote Ischemic Postconditioning on Autonomic Function and Prognosis in Clients With Acute Ischemic Stroke

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02777099
Acronym
IRAS
Enrollment
150
Registered
2016-05-19
Start date
2016-01-31
Completion date
2018-12-31
Last updated
2017-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Keywords

remote ischemic postconditioning, autonomic function, heart rate variability, acute ischemic stroke, prognosis

Brief summary

The purpose of this study is to determine whether remote ischemic postconditioning (RIPostC) initiates autonomic nervous system response and affects the prognosis in patients with acute ischemic stroke.

Detailed description

Remote ischemic postconditioning (RIPostC) has proven effective in reducing the ischemia-reperfusion injury. But the defensive mechanism of RIPostC still unclear. Stroke is frequently associated with autonomic dysfunction. Heart rate variability (HRV) represents the autonomic nervous system activity.This study aims to investigate whether RIPostC correlates with autonomic function and thus predicts prognosis of stroke.

Interventions

Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.

PROCEDUREsham remote ischemic postconditioning

Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.

Sponsors

Guangzhou University of Traditional Chinese Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosed as ischemic stroke according to the Chinese guideline of diagnosis and treatment of acute ischemic stroke 2010 2. Age between 18 to 85 years old 3. initial ischemic stroke within 14 days or less. 4. National Institutes of Health Stroke Scale (NIHSS)score 0-15 5. Modified Rankin Scale(mRS)score 1-4 6. Informed consent

Exclusion criteria

1. Intravenous or arterial thrombolysis, or revascularization 2. Acute myocardial infarction,atrial fibrillation,arrhythmia,or cardiogenic cerebral embolism 3. Systolic Blood Pressure(SBP)\>200mmHg after medication treatment 4. Plasma fibrinogen\>7g/L 5. Upper limb fracture or percutaneous injury 6. Subclavian artery stenosis 7. With severe cardiac,respiratory,hepatic,and renal dysfunction or malignant tumor 8. Simultaneous participation in another interventional study 9. Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Heart Rate Variabilitiesat the time points of baseline and 7 and 30 days after treatmentsHeart rate variability (HRV) is one of the most promising markers represent for autonomic function.We assess the changes from baseline heart rate variability to 7days and 30days.

Secondary

MeasureTime frameDescription
National Institutes of Health Stroke Scale(NIHSS)at the time points of baseline and 7days after treatments.National Institutes of Health Stroke Scale(NIHSS)is a commonly used scale for quantifing the impairment caused by a stroke objectively.
Modified Rankin scale(mRS)at the time points of baseline and 7,30 and 90 days after treatmentsThe modified Rankin Scale (mRS) is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability.The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms.1 - No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.
Barthel Index(BI)at the time points of baseline and 7,30 and 90 days after treatmentsThe Barthel Index scale is an ordinal scale used to measure performance in activities of daily living (ADL). Each performance item is rated on this scale with a given number of points assigned to each level or ranking.It uses ten variables describing ADL and mobility. A higher number is associated with a greater likelihood of being able to live at home with a degree of independence following discharge from hospital.The ten variables addressed in the Barthel scale are:presence or absence of fecal incontinence;presence or absence of urinary incontinence;help needed with grooming;help needed with toilet use help needed with feeding;help needed with transfers (e.g. from chair to bed) help needed with walking;help needed with dressing;help needed with climbing stairs;and help needed with bathing.

Other

MeasureTime frameDescription
Stroke Recurrence90 days after treatmentsStroke recurrence is commonly used to estimate the prognosis of stroke.
Mortality90 days after treatmentsMortality is commonly used to estimate the prognosis of stroke.

Countries

China

Contacts

Primary ContactLin WEI, MD
weilin22@126.com(08620)81887233
Backup ContactMiaomiao MO, Bachelor
momiaomiao11@126.com(08620)81887233

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026